959694-75-8

Upstream product

• 959694-87-2 2-allyloxy-1-(4-methoxyphenyl)ethanone 

Downstream Products

• 959694-22-5 4-[4-allyloxymethyl-4-(4-methoxyphenyl)-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 1401226-04-7 4-[4-hydroxymethyl-4-(4-methoxyphenyl)-3-methyl-2,5-dioxo-imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 959691-92-0 4-[4-allyloxymethyl-4-(4-methoxyphenyl)-3-methyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 959692-07-0 4-[4-hydroxymethyl-4-(4-hydroxyphenyl)-3-methyl-2,5-dioxo-imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 

Relevant academic research and scientific papers

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator

Structural modification performed on a 4-methyl-4-(4-hydroxyphenyl) hydantoin series is described which resulted in the development of a new series of 4-(hydroxymethyl)diarylhydantoin analogues as potent, partial agonists of the human androgen receptor. T

Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such

Compounds of formula (I): wherein X is O or S, R1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R3 and R4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R3 and R4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R3, R4, and R5 being H, R6 and R9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R7 and R8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R7 and R8 not being H or halogen; or one of R7 and R8 is a pharmaceutically acceptable ester or thioester grouping, or R6 is C1-3-alkyl or, together with either R1 or R2, represents C1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.